Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Study Disputes Lymph Node Removal Standard in Melanoma

May 31st 2015

Patients with melanoma who are found to have micrometastases after an initial positive sentinel node biopsy can safely forgo a complete lymph node dissection, thus avoiding the risk of debilitating adverse events from the surgery.

Pivotal T-VEC Data Published Ahead of FDA Approval Decision

May 27th 2015

At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.

As FDA Considers Approval, Weber Discusses Adjuvant Ipilimumab in Melanoma

May 26th 2015

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

Managing Checkpoint Agents' Immune-Related Toxicities

May 20th 2015

As immunotherapy agents enter into greater clinical use in oncology, clinicians are learning to manage immune-related adverse events related to the mechanism of action of these new drugs.

Optimization of Melanoma Treatment Advances Remains a Work in Progress

May 19th 2015

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

Dr. Kevin Kim on T-VEC in Melanoma

May 14th 2015

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.

FDA Activity for Nivolumab and T-VEC in Melanoma, New Lung Cancer Results, and More

May 9th 2015

Sequencing and Timing: Unanswered Questions in Melanoma

May 2nd 2015

CHECKMATE-069: Spectacular Results With Combination Therapy

May 2nd 2015

KEYNOTE-006: Results and Relevance

May 2nd 2015

Dr. Hamid on Using Biomarkers for Immunotherapy in Melanoma

May 1st 2015

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses the possibility of using biomarkers to select immunotherapy as a treatment option for patients with melanoma.

FDA Grants Priority Review to Frontline Nivolumab in Melanoma

April 30th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for previously untreated patients with unresectable or metastatic melanoma.

FDA Panels Support Approval of T-VEC in Melanoma

April 29th 2015

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec (T-VEC) as a treatment for patients with advanced melanoma.

Hodi Speaks to Significance of Phase II Data on Ipilimumab Plus Nivolumab in Melanoma

April 25th 2015

OncLive sat down with F. Stephen Hodi, director, Melanoma Center, director, Center for Immuno-Oncology, Dana-Farber Cancer Institute, to gain further insight into combination and sequencing strategies for patients with melanoma.

2015 AACR Annual Meeting Highlights

April 24th 2015

Adding Nivolumab to Frontline Ipilimumab Improves PFS by 60% in Melanoma

April 20th 2015

Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.

Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma

April 20th 2015

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Novel Doublet and Triplet Combo Studies Explode in Melanoma

April 16th 2015

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.